SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 697,289.23 |
| Enterprise Value ($M) | 732,882.23 |
| Book Value ($M) | 15,846.80 |
| Book Value / Share | 17.65 |
| Price / Book | 44.00 |
| NCAV ($M) | -32,280.80 |
| NCAV / Share | -35.96 |
| Price / NCAV | -21.60 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.20 |
| Return on Assets (ROA) | 0.17 |
| Return on Equity (ROE) | 0.86 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.06 |
| Current Ratio | 1.37 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 41,261.20 |
| Assets | 89,388.80 |
| Liabilities | 73,542.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 45,042.70 |
| Operating Income | 17,040.00 |
| Net Income | 10,590.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 8,817.90 |
| Cash from Investing | -9,301.50 |
| Cash from Financing | 1,230.10 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Lilly Endowment Inc | 10.10 | -0.90 | |
| 13G/A | Pnc Financial Services Group, Inc. | 5.39 | -0.11 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,050,461 | 5,182,414 | 20.27 | |
| 553,103 | 2,831,787 | 19.53 | |
| 965,802 | 4,573,616 | 21.12 | |
| 441,436 | 2,395,076 | 18.43 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ELAN – Elanco Animal Health Incorporated | HYAC – Haymaker Acquisition Corp. 4 |
| JNJ – Johnson & Johnson | MRK – Merck & Co., Inc. |
| NUVB – Nuvation Bio Inc. |